Jochem van Werkum

Showing 1-5 of 5 articles

Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay

Heestermans A, de Boer M, van Werkum J, Mosterd A, Gosselink A, Dambrink J, van Houwelingen K, Koopmans P, Hamm C, Zijlstra F, ten Berg J, van't Hof A

August 30, 2011 | 10.4244/EIJV7I4A73

Triggering mechanisms of stent thrombosis

Zwart B, van Werkum J, Heestermans A, Kelder J, Zomer A, van't Hof A, Verheugt F, ten Berg J

January 20, 2011

Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial

Timmer J, ten Berg J, Heestermans A, Dill T, van Werkum J, Dambrink J, Suryapranata H, Ottervanger J, Hamm C, van't Hof A

August 15, 2010

Platelet reactivity as a risk-factor for stent thrombosis: can this be one of the currently available appropriate methods to determine platelet reactivity?

van Werkum J, ten Berg J

August 20, 2008

Point-of-care platelet function testing in patients undergoing PCI: is it ready for use in clinical practice?

ten Berg J, van Werkum J

August 20, 2008

1

Latest news

EAPCI/ACVC consensus on pVADs, coronary physiology mini focus, a new analysis from the COAPT trial, patient selection for tricuspid interventions and more…

Treatment of secondary mitral regurgitation in patients with heart failure

Marco Metra et al

This Week's JAA's: Principles and Pitfalls in CFT, Brachial access for PCI....

Coronary flow capacity: where to next?

Nils P. Johnson

Joint EAPCI/ACVC expert consensus document on pVADs

EuroIntervention's new impact factor!

STATE OF THE ART

Completeness of Revascularisation in ACS Patients with Multivessel Disease

Valeria Paradies et al.

Valvular disease